In 2026, Nalvurikenz officially announced the release of its new AI-powered trading platform, integrating unique features and functionalities to simplify the trading process using a combination of artificial intelligence, live data analytics, and advanced automation.
COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.
Madrid, Spain, June 13, 2026 (GLOBE NEWSWIRE) -- A 2026 company-aligned overview of how the Glacier Breeze Portable AC is presented across official product materials, including its Twin Frost Jet design, evaporative cooling technology, cooling cartridge system, and key considerations for consumers before purchasing.
SHANGHAI, June 13, 2026 /PRNewswire/ -- AESC, a global leader in high-performance batteries and energy storage systems, and Prevalon Energy, a Mitsubishi Power Americas...
SHANGHAI, June 13, 2026 /PRNewswire/ -- AESC, a global leader in high-performance batteries and energy storage systems, and Prevalon Energy, a Mitsubishi Power Americas...
RIYADH, Saudi Arabia, June 13, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) will use its participation at HLTH Europe 2026, taking place from June 15 to 18 in Amsterdam, to advance a clear message: artificial intelligence in healthcare will only scale when institutions can prove that it is safe, reliable, governed, and trusted by clinicians and patients.
Starting June 13, M14 PLUS and S14 PLUS Drop to $399.99, Bringing Advanced Self-Cleaning Roller Mop Technology Into the Sub-$400 SegmentSAN FRANCISCO, June 13,...
SHANGHAI, June 13, 2026 /PRNewswire/ -- AESC, a global leader in high-performance batteries and energy storage systems, and Prevalon Energy, a Mitsubishi Power Americas...
BEERSE, BELGIUM, June 13, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the investigational Phase 3 MonumenTAL-3 study.1 The results showed that TALVEY® (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72.0%, and clinically meaningful reduction of up to 53.0% in the risk of death, compared to the standard regimen of daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM).1 Results showed a progression-free survival (PFS) rate of up to 81.3% versus standard of care (51.2%) and an overall survival (OS) rate of up to 89.2% versus standard of care (79.1%) at 24 months.1